Previous close | 231.60 |
Open | 231.40 |
Bid | 231.20 x 0 |
Ask | 231.30 x 0 |
Day's range | 230.50 - 232.30 |
52-week range | 177.45 - 245.50 |
Volume | |
Avg. volume | 372,454 |
Market cap | 68.463B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 22.52 |
EPS (TTM) | 10.27 |
Earnings date | 08 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 255.44 |
Sobi plans to publish its report for the fourth quarter and full year of 2022 on 8 February 2023 at 08:00 CET.
Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa (formerly BIVV001), a potential new medicine for haemophilia A. These data demonstrate the clinical benefits of normal to near-normal factor activity levels (>40%) for the majority of the week achieved by once weekly efanesoctocog alfa dosing. Efanesoctocog alfa is currently under priority regulatory review in the US with a targ
Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in September by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA).